

# **Objective Assessment of Disease Activity and Remission in Rheumatoid Arthritis**

## ***Thesis***

*Submitted in Partial Fulfillment of the requirements of  
MD Degree in Physical Medicine, Rheumatology  
and Rehabilitation*

## ***By***

**Sherihan Mahdy Salama**

*M.B., B.Ch., M.Sc.*

*Faculty of Medicine- Ain Shams University*

## ***Under the Supervision of***

**Prof. Dr. Fatma Kamel Mohamed Abdel Motaal**

*Professor of Physical Medicine, Rheumatology and Rehabilitation Department  
Faculty of Medicine, Ain Shams University*

**Prof. Dr. Mona Gamal El Husseiny**

*Professor of Physical Medicine, Rheumatology and Rehabilitation  
Department*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr. Ireen Raouf Amin**

*Professor of Physical Medicine, Rheumatology and Rehabilitation  
Department*

*Faculty of Medicine, Ain Shams University*

**Dr. Hossam Moussa Sakr**

*Assistant professor in Radiodiagnosis Department,  
Faculty of Medicine, Ain Shams University*

***Faculty of Medicine  
Ain Shams University***

**2016**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ  
لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْحَكِيمُ

سورة البقرة  
الآية (٣٣)

صَدَقَ اللَّهُ الْعَظِيمُ

## Acknowledgments

*First of all, thanks to **ALLAH** the most merciful and the most graceful for giving me the strength to carry out this work and for giving me such a wonderful and supporting family.*

*I would like to express my sincere gratitude to **Prof. Dr. Fatma Kamel Abdel Motaal**, former head of Physical Medicine, Rheumatology and Rehabilitation department, Ain Shams University for her great help and constructive guidance.*

*Also, I would like to express my deepest gratitude to **Prof. Dr. Mona Gamal El Din El Hussieny**, Professor of Physical Medicine, Rheumatology and Rehabilitation, Ain Shams University, for her help, precious advice and her valuable observation all through the work.*

*I am greatly grateful to **Prof. Dr. Ireen Raof Amin**, Professor of Physical Medicine, Rheumatology and Rehabilitation, Ain Shams University, for her close supervision and continuous help all through this work.*

*My gratitude to **Dr. Hossam Moussa Saker**, assistant Professor of Radiodiagnosis, Ain Shams University, for his help in performing radiological work in this thesis.*

*With my deepest gratitude to my colleagues in our department for offering help whenever I need during this work.*

*Last but not least, my endless gratitude to my parents, my husband for their cooperative spirit and great assistance and their moral support.*

# List of Contents

<i>Title</i>	<i>Page No.</i>
Introduction .....	1
Aim of the work .....	7
Review of Literature .....	8
Patients and methods.....	109
Results .....	131
Discussion.....	193
Summary and Conclusion .....	228
Recommendations .....	236
Appendices .....	237
References .....	247
Arabic Summary .....	—

# List of Tables

<i><b>Table No.</b></i>	<i><b>Title</b></i>	<i><b>Page No.</b></i>
<b>Table (1):</b>	ACR classification criteria for rheumatoid arthritis (1987) .....	40
<b>Table (2):</b>	The 2010ACR/EULAR classification criteria for RA .....	42
<b>Table (3):</b>	Main immune-targeted therapies for rheumatoid arthritis .....	52
<b>Table (4):</b>	Remission criteria for rheumatoid arthritis .....	69
<b>Table (5):</b>	OMERACT definitions of RA lesions detected by MRI .....	102
<b>Table (6):</b>	Showing the frequency distribution of the RA patients in each group (total= 50) .....	133
<b>Table (7):</b>	Comparison of age among study groups .....	134
<b>Table (8):</b>	Comparison of sex distribution of each group .....	135
<b>Table (9):</b>	Disease duration of patients in each group (in year) .....	136
<b>Table (10):</b>	Showing ACR remission criteria among patients ...	137
<b>Table (11):</b>	Showing range of SDAI score of the patients in comparison to their DAS28 activity group .....	138

<b>Table (12):</b> Showing degree of activity according to SDAI score of the patients .....	139
<b>Table (13):</b> Duration of morning stiffness in patients of each group .....	140
<b>Table (14):</b> Distribution of inflammation among 44 joints examined in patients of each group .....	141
<b>Table (15):</b> Comparing the 28 tender joint counts in different patients' groups .....	142
<b>Table (16):</b> Comparing the 28 swollen joint counts in different patients' groups .....	142
<b>Table (17):</b> Distribution of joint deformities in patients in each group .....	144
<b>Table (18):</b> Number and percent of patients with extraarticular manifestations .....	145
<b>Table (19):</b> ESR and CRP in patients and in controls .....	147
<b>Table (20):</b> Comparing different groups of patients as regards their drug treatment .....	148
<b>Table (21):</b> MHAQ score among study groups .....	149
<b>Table (22):</b> DHI score among study groups .....	150
<b>Table (23):</b> X-ray erosion scores among study groups .....	152

<b>Table (24):</b>	Total X-ray scores among study groups .....	153
<b>Table (25):</b>	The correlation between DAS28 score and the X-ray erosion and total .....	154
<b>Table (26):</b>	GSJC among study groups .....	156
<b>Table (27):</b>	GSJS among study groups .....	157
<b>Table (28):</b>	The correlation between DAS28 score and the GSJC and GSJS .....	158
<b>Table (29):</b>	Synovial thickness of examined joints in mm .....	159
<b>Table (30):</b>	The number (and percentage) of joints showing different scores of synovitis by GSUS in each group .....	159
<b>Table (31):</b>	PDJC among study groups .....	163
<b>Table (32):</b>	PDJS among study groups .....	164
<b>Table (33):</b>	The correlation between DAS28 score and the PDJC and PDJS .....	165
<b>Table (34):</b>	The number (and percentage) of joints showing each score of PD activity in different groups .....	166
<b>Table (35):</b>	RI in affected joints according to their score .....	168
<b>Table (36):</b>	US erosion count and score among study groups ...	169



<b>Table (37):</b> Correlation between DAS28 score and US erosion count& score .....	170
<b>Table (38):</b> The number (and percentage) of joints showing each score of US erosions in different groups .....	171
<b>Table (39):</b> MRI synovitis count and score among study groups .....	174
<b>Table (40):</b> The correlation between DAS28 score and the MRI synovitis count and score .....	175
<b>Table (41):</b> The number (and percentage) of joints showing each score of MRI synovitis in different groups .....	176
<b>Table (42):</b> MRI BME count and score in study groups .....	179
<b>Table (43):</b> The correlation between DAS28 score and the MRI BME count and score .....	180
<b>Table (44):</b> MRI erosion count and score among study groups .....	182
<b>Table (45):</b> The correlation between DAS28 score and the MRI erosion count and score .....	183
<b>Table (46):</b> Difference between US and MRI synovitis joint count .....	187
<b>Table (47):</b> US and MRI synovitis score difference among study groups .....	188

<b>Table (48):</b>	Difference between US and MRI synovitis joint count .....	191
<b>Table (49):</b>	US and MRI erosion score among study grades .....	192

# List of Figures

<b><i>Figure No.</i></b>	<b><i>Title</i></b>	<b><i>Page No.</i></b>
<b>Figure (1):</b>	Helper T-Cell (Th) Subgroups and Effector Functions: The cytokine profile .....	12
<b>Figure (2):</b>	The T-cell activation .....	15
<b>Figure (3):</b>	TNF- $\alpha$ actions relevant to the pathogenesis of RA .....	20
<b>Figure (4):</b>	Complementary action if TNF and IL-1 .....	23
<b>Figure (5):</b>	Inflammatory pathways activated by IL-6 .....	25
<b>Figure (6):</b>	Structural difference between normal and rheumatoid joint .....	30
<b>Figure (7):</b>	Stages in the process of angiogenesis .....	35
<b>Figure (8):</b>	Summary of treatment of RA .....	55
<b>Figure (9):</b>	DAS28 tender and swollen joints .....	64
<b>Figure (10):</b>	Joint effusion on ultrasonography .....	90
<b>Figure (11):</b>	Synovial changes on ultrasonography .....	91
<b>Figure (12):</b>	Joints involved in DAS28 .....	114
<b>Figure (13):</b>	Visual analogue scale .....	114
<b>Figure (14):</b>	Synovial effusion grade 1-3 on B mode: proximal inter-phalangeal joint .....	121

<b>Figure (15):</b> Synovial hypertrophy grade 1-3 on B mode: proximal inter-phalangeal joint .....	122
<b>Figure (16):</b> Synovitis grade 1-3 PD activity: dorsal view of a metacarpophalangeal joint .....	124
<b>Figure (17):</b> Distribution of RA patients among different groups according to their DAS28 score .....	133
<b>Figure (18):</b> Percentage of joints showing different scores of synovitis by GSUS in each group .....	160
<b>Figure (19):</b> Fifth MCP joint with grade 2 synovial hypertrophy (arrow). .....	160
<b>Figure (20):</b> Second MCP joint with grade 3 synovial hypertrophy (arrow) .....	161
<b>Figure (21):</b> Third MCP joint with grade 1 effusion (star) and grade 2 synovial hypertrophy (arrow) .....	161
<b>Figure (22):</b> Percentage of joints showing each score of PD activity in different groups .....	166
<b>Figure (23):</b> Third MCP joint with grade 1 PD sign .....	167
<b>Figure (24):</b> Wrist joint with grade 2 PD sign .....	167
<b>Figure (25):</b> Percentage of joints showing each score of US erosions in different groups .....	172
<b>Figure (26):</b> Second MCP joint showing grade 2 bone (arrow) ..	172

<b>Figure (27):</b> The percentage of joints showing each score of MRI synovitis in different groups .....	178
<b>Figure (28):</b> Multiple areas of synovitis in wrist joint in MRI cut (stars) .....	178
<b>Figure (29):</b> Extensive BME of carpal bones in wrist joint in MRI cut .....	180
<b>Figure (30):</b> Multiple areas of erosions in wrist joint in MRI cut (stars) .....	184
<b>Figure (31):</b> Number of joints showing synovitis by clinical examination, US and MRI .....	185
<b>Figure (32):</b> Number of joints showing erosions by x-ray, US and MRI. ....	189

## List of Abbreviations

<b>Abb.</b>	<b>Meaning</b>
<b>ACPA</b> .....	Anti-citrullinated protein antibodies
<b>ACR</b> .....	American College of Rheumatism
<b>AP1</b> .....	Activation protein 1
<b>APC</b> .....	Antigen presenting cells
<b>APRIL</b> .....	Proliferation-inducing ligand
<b>BLyS</b> .....	B-lymphocyte stimulator
<b>BME</b> .....	Bone marrow edema
<b>CC</b> .....	Chemokine ligand 21
<b>CCL21</b> .....	Chemokine ligand 21
<b>CCL23</b> .....	Chemokine ligand 23
<b>CDAI</b> .....	Clinical disease activity index
<b>cox-2</b> .....	Cyclo-oxygenase type 2
<b>CRP</b> .....	C-reactive protein
<b>CTLA-4</b> .....	Cytotoxic T lymphocyte antigen-4
<b>CTLA4-Ig</b> .....	Cytotoxic T lymphocyte antigen-4 immuno- globulin
<b>CXC</b> .....	Chemokine ligand 14
<b>CXCL13</b> .....	Chemokine ligand 13
<b>DAS</b> .....	Disease activity score

**DMARD** .....Disease modifying anti rheumatic drugs

**ECM** .....Extra- cellular matrix

**ESR**.....Erythrocyte sedimentation rate

**EULAR** .....European League against rheumatism

**FLS** .....Fibroblast-like type B synoviocytes

**GM-CSF** .....Granulocyte–macrophage colony stimulating factor

**HDA**.....High disease activity

**HDL** .....High-density lipoprotein

**HLA** .....Human Leucocytic antigen

**IC** .....Immune complex

**ICAM-1** .....Intercellular adhesion molecule-1

**ICOS** .....Inducible costimulator

**IL** .....Interleukin

**IL-1Ra** .....IL-1 receptor antagonist

**JAK** .....Janus kinase

**LDA** .....Low disease activity

**LDL** .....Low density lipoprotein

**LFA-1** .....lymphocyte function-associated antigen

**MAPK** .....Mitogen activated protein kinase

**MDA** .....Moderate disease activity